TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
IMVT

Immunovant Inc

Healthcare · Biotechnology

34.50$ -7.4% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

Immunovant Inc (IMVT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 852 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IMVT
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
292 711 667 590 516 421 776 661 583 1,052 957 852
291 711 666 589 507 413 768 652 574 1,043 949 851
270 691 635 560 473 375 714 599 522 995 902 798
270 691 635 560 473 375 714 599 522 995 902 798
1.4 1.0 5.5 2.4 1.9 2.2 2.5 1.9 2.0 1.6 3.9 0.7
– 0.0 – – – – – – – – – –
40 32 49 45 67 68 69 53 63 66 104 117
40 32 49 45 67 68 69 53 63 66 104 117
0.6 0.3 0.1 0.1 0.0 0.0 0.1 – – – 0.1 –
7.5 3.9 7.2 11 21 20 18 7.8 6.9 8.6 7.5 10
252 679 618 545 449 353 707 609 520 986 853 735
-699 -750 -826 -913 -1,022 -1,133 -1,240 -1,360 -1,487 -1,597 -1,745 -1,898
131 145 145 146 146 147 152 171 174 182 204 206

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?